Recent News

• 03.31.2025 - Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 03.31.2025 - Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
• 02.26.2025 - Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
• 02.26.2025 - Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
• 02.18.2025 - UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
• 02.18.2025 - UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
• 02.18.2025 - UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
• 02.18.2025 - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
• 02.18.2025 - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
• 02.11.2025 - Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February

Recent Filings

• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.18.2025 - EX-99.1 EX-99.1
• 02.18.2025 - 8-K/A Current report
• 02.18.2025 - 8-K Current report